Jun 18th, 2007, 15:23
|
只看该作者 #30 | |
|
Senior Member
 
注册日期: Jul 2004
帖子: 451
声望: 12199
  |
引用:
Another 2.65 million shares were immediately listed as being for resale by selling shareholders. It was not clear from reports whether these shares had been placed. After the IPO, 19.5 million shares of Shenghuo are outstanding. Seeking Alpha China Shenghuo Pharmaceutical Doubles After Its IPO Monday June 18, 7:47 am ET ChinaBio Today submits: China Shenghuo Pharmaceutical Holdings, Inc. (AMEX: KUN - News) listed its shares on the American Stock Exchange on Thursday, June 14, after completing a very small, 400,000-share IPO that seems more like a private placement. The shares were priced at $3.50, led by the sole underwriter: WestPark Capital in Los Angeles. ADVERTISEMENT WestPark was instrumental in forming the company in 2005. Another 2.65 million shares were immediately listed as being for resale by selling shareholders. It was not clear from reports whether these shares had been placed. After the IPO, 19.5 million shares of Shenghuo are outstanding. Among other activities for China Shenghuo, West Park brokered a private placement in 2005 of 2 million shares at $.90 each ($1.8 million gross proceeds), of which almost $200,000 went to West Park for its work. Perhaps because of the small float, Shenghuo fared very well – in fact excellently – in open market trading. After opening at $4.40 on Thursday afternoon, the shares doubled over the IPO price in the next day and a half of trading. At the close on Friday, June 14, Shenghuo stood at an even $7.00, up $2.27 or 49% on the day. At 208,000 shares traded, volume was not particularly high, though that was just over 50% of the shares sold in the IPO. At $7 per share, the market is giving Shenghuo a value of $137 million. In 2006, China Shenghuo made a profit of $3.6 million on $20 million of revenue. That works out to 17 cents per share. In terms of business, China Shenghuo was formed in 1995. It combines traditional Chinese medicines with western pharmacology, building pharmaceutical, nutritional and cosmetic product lines around Panax notoginseng, a form of ginseng that invigorates and builds blood. A full 80% of its revenues come from Xuesaitong Soft Capsules, which are given to treat cardiovascular and cerebrovascular disease. It has a total of 31 state-approved medications. Almost all of its sales are in China, though small amounts of its drugs are exported to other countries in Asia. |
|
|
|
|
Jun 18th, 2007, 15:30
|
只看该作者 #32 |
|
Senior Member
  
注册日期: Jul 2004
帖子: 5,748
积分:3
精华:3
声望: 1850049
|
本人收集的kun资料 --------------------------------- 成立于1997年的圣火制药，不仅被认定为高新技术企业，具备自营进出口资格，而且在全国医药界具有明显的差别优势，公司独家开发和生产的国家中药新药"血塞通软胶囊"（商标名：理洫王）是云南省首个获批办"国药准字"的新药，也是迄今为止全国"三七"制剂中唯一被国家药监局正式批准生产的新药。公司申报的"三七高技术产业规模化生产"项目，被列入了国家发改委"西部开发高新技术产业化示范工程"和"云南省绿色产业示范化工程"。公司的年生产能力在15亿元以上。 近5年，圣火药业销售额以每年50%的速度递增。圣火制药的目标是：2008年销售额要达到10个亿，2012年达到20亿至25亿。而成功在美国上市，被认为对实现这一目标有着重要的推动意义。 |
|
|
|
